A 2-Part Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2019
At a glance
- Drugs JNJ-63733657 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 08 Feb 2019 Planned number of patients changed from 64 to 80.
- 21 Sep 2018 Planned End Date changed from 4 Jul 2019 to 16 Oct 2019.
- 31 Aug 2018 Biomarkers information updated